SSBP2 and acute lymphoblastic leukemia: This may be a treatment-relevant finding since JAK2-kinase rearranged ALL with fusions of JAK2 to ATF7IP, EBF1, PAX5, SSBP2, RNPC3, GOLGA5, PCM1 and their effective inhibition by treatment with the JAK inhibitor ruxolitinib have been described previously in anecdotal cases [25,26,27,28].